Ken Griffin
ZVSA

Ken Griffin’s ZyVersa Therapeutics ZVSA Stock Holding History

Ken Griffin’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,499
Closed -$13.5K – 15557
2023
Q4 		$13.5K Buy
+1,499
New +$42.2K ﹤0.01% 12927

Other funds holding ZVSA

TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ken Griffin's ZVSA Position: Q1 2024 in Review

Ken Griffin sold out of ZyVersa Therapeutics (ZVSA) in Q1 2024, closing a stake of 1,499 shares — an estimated $13.5K sold.

Ken Griffin first reported a position in ZVSA in Q4 2023 and held it in 1 quarter. The position peaked at $13.5K in Q4 2023. 7 funds tracked by Wall St. Rank hold ZVSA as of Q1 2024.

  • Ken Griffin reported no remaining ZyVersa Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Ken Griffin sold 1,499 ZyVersa Therapeutics shares in Q1 2024, an estimated $13.5K.
  • Ken Griffin first reported a position in ZyVersa Therapeutics in Q4 2023 and held it in 1 quarter.
  • Ken Griffin's ZyVersa Therapeutics position peaked at $13.5K in Q4 2023.
  • 7 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.